The latest: Shares of AIM Vaccine Co. Ltd. (6660.HK), China’s second-largest maker of non-Covid vaccines, surged on their second trading day Friday after a modest 3.1% gain the previous day in their Hong Kong trading debut. The stock is one of the few recent new listings to rise on its debut day.

Looking up: The local portion of the company’s offering of 971,600 shares was subscribed to by 2,520 investors who sought to buy a total of 3,062,000 shares, representing an oversubscription rate of approximately 2.15 times.

Take Note: The company offered only 0.8% of its share capital and raised just HK$70.01 million ($8.9 million), making it one of the smallest IPOs in recent months.

Digging Deeper: AIM Vaccine has traveled a bumpy road to becoming a listed company. It filed to list on Shanghai’s Nasdaq-style STAR Market in 2020, but that got nowhere. In June last year it shifted its IPO destination to Hong Kong, but its application was rejected less than a month later. In September last year, it filed a second time for a Hong Kong listing, but that application lapsed six months later. The company finally made the cut on its third try, passing a hearing last month that paved the way for its Thursday debut.

Market Reaction: AIM Vacccine’s shares rose 38.1% to HK$23 at the midday break on Friday. When combined with the 3.1% debut-day gain, the stock is now up 42.3% from its IPO price.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

New Oriental provides education services

New Oriental gets new lesson from souring U.S.-China relations

China’s leading private provider of education services blamed changing international relations for a slowdown in its business catering to students planning to study abroad Key Takeaways: New Oriental’s revenue from…